Alnylam Pharmaceuticals (LTS:0HD2) Days Payable : 68.74 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Alnylam Pharmaceuticals Days Payable?

Alnylam Pharmaceuticals's average Accounts Payable for the three months ended in Dec. 2023 was $65 Mil. Alnylam Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $86 Mil. Hence, Alnylam Pharmaceuticals's Days Payable for the three months ended in Dec. 2023 was 68.74.

The historical rank and industry rank for Alnylam Pharmaceuticals's Days Payable or its related term are showing as below:

LTS:0HD2' s Days Payable Range Over the Past 10 Years
Min: 82.18 Med: 211.78 Max: 8918.7
Current: 82.18

During the past 13 years, Alnylam Pharmaceuticals's highest Days Payable was 8918.70. The lowest was 82.18. And the median was 211.78.

LTS:0HD2's Days Payable is ranked worse than
62.04% of 714 companies
in the Biotechnology industry
Industry Median: 146.16 vs LTS:0HD2: 82.18

Alnylam Pharmaceuticals's Days Payable declined from Dec. 2022 (123.41) to Dec. 2023 (68.74). It may suggest that Alnylam Pharmaceuticals accelerated paying its suppliers.

Alnylam Pharmaceuticals Days Payable Historical Data

The historical data trend for Alnylam Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Days Payable Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

798.04

238.14

163.29

185.42

90.32

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															123.41	133.32	65.19	72.29	68.74

Competitive Comparison of Alnylam Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Days Payable falls into.

Alnylam Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Alnylam Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (98.094	+	55.519)	/	2 )	/	310.406	*	365
=	76.8065					/	310.406	*	365
=	90.32

Alnylam Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (73.84	+	55.519)	/	2 )	/	85.858	*	365 / 4
=	64.6795					/	85.858	*	365 / 4
=	68.74

Alnylam Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (LTS:0HD2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (LTS:0HD2) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (LTS:0HD2) Headlines

No Headlines